

West London Mental Health NHS Trust Performance in Initiating Q2 16/17

NHS Permission Studies

Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Comments
15/NE/0269	188082	NHS Permission	A Parallel-Group, Double Blind Long Term Safety Trial of MK-8931 in Subjects with Alzheimer's Disease.	22/03/2016	23/03/2016	Yes	10/05/2016	1	48	49	Yes	

HRA Approval Studies

Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Comments
16/NE/0191	202345	HRA Approval	A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)	No		Within 70 day benchmark period	09/05/2016	24/08/2016	22/08/2016	24/08/2016	30/08/2016	Please Select...	02/09/2016	

West London Mental Health NHS Trust Performance in Delivery Q2 16/17

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16242	150835/LNW	150835	DEME 3598 - STARBRIGHT Randomised, double blind, parallel- group, placebo-controlled study of Lu AE58054 in patients with mild moderate Alzheimer's disease treated with an acetylcholinesterase inhibitor; study 3	Number Agreed	8	8	Date Agreed	30/06/2016	9	30/06/2016	0	Recruitment Finished	Recruitment target achieved
16284	14/SS/0049	143780	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medi	Number Agreed	12	12	Date Agreed	31/12/2016	46	04/11/2015	0	Withdrawn By Sponsor	Study withdrawn/terminated by sponsor
16285	15/EM/0094	171455	A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication	Number Agreed	12	12	Date Agreed	31/07/2016	2	04/11/2015	0	Withdrawn By Sponsor	Study withdrawn/terminated by sponsor